Accessibility StatementSkip Navigation ROME, 15 novembre 2025 /PRNewswire/ -- La Fondazione Telethon annonce l'avis positif émis par le Comité des médicaments à usage humain (CHMP) de l'Agence européenne des médicaments (EMA), recommandant l'autorisation de mise sur le marché dans l'Union européenne de Waskyraâ"¢, une thérapie génique ex vivo destinée à traiter le syndrome de Wiskott-Aldrich (WAS), une immunodéficience primaire rare et potentiellement mortelle. La Fondazione Telethon est la premiè ...

Core Insights - RAPT Therapeutics is an immunology-focused biotech company that has previously been assessed as having a market value significantly exceeding its data [1] Company Analysis - The company has generated considerable market value, which raises questions about the sustainability of its valuation relative to its clinical data [1] Industry Context - The article emphasizes the importance of understanding the science behind biotech investments to avoid potential pitfalls in the sector [1]

Core Viewpoint - The article discusses the bullish outlook for small- and mid-cap stocks, highlighting their potential for earnings growth as the market approaches the end of the year, with expectations for a catch-up in performance compared to large-cap stocks driven by favorable market conditions and improved earnings guidance [2][3][4]. Small and Mid-Cap Stocks Outlook - Scott Chronert, Citi's U.S. equity strategist, emphasizes that small and mid-cap stocks are expected to transition from low single-digit earnings growth in 2025 to low double-digit growth in 2026 [3]. - The recent Q3 earnings reports from small-cap companies have shown raised guidance for Q4 and 2026, indicating a positive trend for these stocks [3]. - The small-cap sector is coming off a two-year period of low earnings, which sets a favorable comparison for future growth [3]. Methodology for Stock Selection - The list of the 10 hottest small-cap stocks was compiled using the Finviz Stock Screener, WSJ, Yahoo Finance, and Insider Monkey's Q2 2025 database, focusing on stocks with market capitalizations between $300 million and $2 billion that gained over 50% in the past six months [7]. - Stocks were ranked based on the number of hedge fund holders, indicating interest from institutional investors [7][8]. Featured Small-Cap Stocks - **Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH)**: - Market Capitalization: $1.88 billion - 6-Month Performance: 55.36% - Revenue grew by 22.2% year-over-year to $621.9 million, exceeding analyst expectations [10][12]. - Adjusted EBITDA increased by 67.5% year-over-year to $80.1 million, with management raising full-year revenue guidance to over $2.375 billion [13][14]. - **Spyre Therapeutics, Inc. (NASDAQ:SYRE)**: - Market Capitalization: $1.81 billion - 6-Month Performance: 56.40% - Positive interim Phase 1 results for SPY003, a novel treatment for inflammatory bowel disease, were announced, showing a favorable safety profile [15][16]. - The company is well-positioned financially with a substantial cash runway to support operations until the second half of 2028 [18].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Repare Therapeutics Inc. to XenoTherapeutics, Inc. for Repare shareholders [1] Summary by Relevant Sections - Proposed Transaction Details: Upon closing, each Repare shareholder is expected to receive a cash payment of $1.82 per share, along with one non-transferable contingent value right for potential additional cash payments under certain conditions [1]

Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in compliance with manufacturing regulations [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and the implications for its product, briquilimab, which could negatively impact its regulatory and commercial prospects [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in previous years [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. - It is important to note that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

Core Insights - The Ademi Firm is investigating Repare for potential breaches of fiduciary duty related to its transaction with XenoTherapeutics [1][3] - Repare shareholders are set to receive approximately $1.82 per share in cash at closing, along with a non-transferable contingent value right (CVR) per share [2] - The CVRs will entitle shareholders to a percentage of future proceeds from partnerships with Bristol-Myers Squibb, Debiopharm, and DCx Biotherapeutics, with percentages ranging from 90% to 75% over a 10-year period [2] Transaction Details - The final cash payment to Repare shareholders will depend on the company's cash balance at closing after deducting transaction costs and liabilities [2] - The transaction agreement includes provisions that limit competing offers for Repare, imposing penalties for accepting alternative bids [3] Investigation Focus - The investigation by the Ademi Firm centers on whether the Repare board of directors is adequately fulfilling their fiduciary duties to all shareholders amid the transaction [3]

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that during the class period, the defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors over the years [4].

Company Updates - Cidara Therapeutics, Inc. (NASDAQ:CDTX) experienced a stock price surge to $217.89, marking a 105.57% increase, attributed to advancements in its lead product candidate, rezafungin acetate, and the Cloudbreak platform targeting high mortality fungal infections and COVID-19 [1][4] - Cycurion, Inc. (NASDAQ:CYCU) saw its stock rise to $6.10, a 45.93% increase, driven by its focus on AI-driven cybersecurity solutions for government and critical infrastructure [2][4] Industry Insights - The significant price movements of these companies underscore the importance of innovation and strategic focus in enhancing company value within their respective sectors [3] - The growing emphasis on cybersecurity solutions highlights a key growth area in the digital age, positioning Cycurion as a critical player in this market [2][3]

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock jumped on Friday after the FDA issued a new boxed warning for Elevidys. The updated approval follows recent reports of fatal liver injury in non-ambulatory pediatric patients who received the gene therapy. SRPT stock is moving. Watch the price action here. The FDA has updated the labeling for Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), by adding its highest-level safety warning—a Boxed Warning—and restricting its approved use. Read Next: Shk ...

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Cidara Therapeutics, Inc. (NASDAQ: CDTX) related to its sale to Merck Sharp & Dohme LLC. Under the terms of the proposed transactio ...